These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36208947)

  • 21. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.
    Jeffers BW; Robbins J; Bhambri R
    Am J Ther; 2017; 24(1):e68-e80. PubMed ID: 26588586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.
    Zanchetti A; Liu L; Mancia G; Parati G; Grassi G; Stramba-Badiale M; Silani V; Bilo G; Corrao G; Zambon A; Scotti L; Zhang X; Wang H; Zhang Y; Zhang X; Guan TR; Berge E; Redon J; Narkiewicz K; Dominiczak A; Nilsson P; Viigimaa M; Laurent S; Agabiti-Rosei E; Wu Z; Zhu D; Rodicio JL; Ruilope LM; Martell-Claros N; Pinto F; Schmieder RE; Burnier M; Banach M; Cifkova R; Farsang C; Konradi A; Lazareva I; Sirenko Y; Dorobantu M; Postadzhiyan A; Accetto R; Jelakovic B; Lovic D; Manolis AJ; Stylianou P; Erdine S; Dicker D; Wei G; Xu C; Xie H; Coca A; O'Brien J; Ford G
    J Hypertens; 2014 Sep; 32(9):1888-97. PubMed ID: 24979303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure reduction and ACE inhibition in secondary stroke prevention: mechanism uncertain.
    Davis SM; Donnan GA
    Stroke; 2003 May; 34(5):1335-6. PubMed ID: 12702835
    [No Abstract]   [Full Text] [Related]  

  • 26. Practical guide for the use of PCSK9 inhibitors in Portugal.
    Fontes-Carvalho R; Marques Silva P; Rodrigues E; Araújo F; Gavina C; Ferreira J; Morais J
    Rev Port Cardiol (Engl Ed); 2019 Jun; 38(6):391-405. PubMed ID: 31324407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
    Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
    G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic.
    Chmelík Z; Vaclová M; Lánská V; Laštůvka J; Vrablík M
    Cent Eur J Public Health; 2020 Jun; 28(2):114-119. PubMed ID: 32592555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
    Wu HY; Huang JW; Lin HJ; Liao WC; Peng YS; Hung KY; Wu KD; Tu YK; Chien KL
    BMJ; 2013 Oct; 347():f6008. PubMed ID: 24157497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F; Del Vecchio L; Andrulli S; Colzani S
    Kidney Int Suppl; 2002 Dec; (82):S53-60. PubMed ID: 12410856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High blood pressure and coronary heart disease. Are there new therapeutic options?].
    Motz W
    Herz; 2004 May; 29(3):255-65. PubMed ID: 15167951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and single-pill combination].
    Okura T; Higaki J
    Clin Calcium; 2010 Jan; 20(1):61-8. PubMed ID: 20048435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of lipid management in acute coronary syndrome.
    Fujisue K; Tsujita K
    J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC; Heran BS; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [AT1-blockers in the treatment of hypertension: summary].
    Widimský J
    Vnitr Lek; 2016 Feb; 62(2):107-13. PubMed ID: 27172437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.